Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Switch Therapeutics is rethinking cell-type specificity, building precision RNAi therapeutics for the brain.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Han, S.-p et al. Mol. Ther. Nucleic Acids 27, 797–809 (2022).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marchal, I. Editor’s pick: Switch Therapeutics. Nat Biotechnol 42, 1486–1487 (2024). https://doi.org/10.1038/s41587-024-02423-9
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-024-02423-9
